Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients

被引:6
|
作者
Dadgar, Habibollah [1 ]
Seyedi Vafaee, Manouchehr [2 ,3 ]
Norouzbeigi, Nasim [1 ]
Jafari, Esmail [4 ]
Gholamrezanezhad, Ali [5 ]
Assadi, Majid [4 ]
机构
[1] Imam Reza Int Univ, RAZAVI Hosp, RAZAVI Canc Res Ctr, Mashhad, Razavi Khorasan, Iran
[2] Odense Univ Hosp, Dept Nucl Med, Odense, Denmark
[3] Univ Southern Denmark, BRIDGE, Translat Neurosci, Odense, Denmark
[4] Bushehr Univ Med Sci, Dept Mol Imaging & Radionuclide Therapy, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Bushehr, Iran
[5] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA
关键词
68Ga-PSMA-11; prostate cancer; PET; CT; prostate specific antigen; SUVmax;
D O I
10.1177/0391560321993544
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: This study was conducted to compare the early static (3-6 min post-injection (p.i.)) and standard whole body (1 h, p.i.) 68Ga-PSMA-11 PET/CT imaging for detection of lesions in prostate cancer (PC) patients. Materials and methods: In this study, PC patients suspected of recurrence underwent 68Ga-PSMA-11 PET/CT. Early static images were acquired from the pelvis and the lower abdomen 3-5 minutes after radiotracer injection and, a routine whole body scan was performed from the skull to the mid-thigh 1 h after injection. Quantitative analysis (SUVmax) was evaluated in suspicious lesions. Results: Of 19 evaluated PC patients with a median age of 72 +/- 1.66 years (range: 55-85 years) and prostate-specific antigen (PSA) of 1.72 +/- 6.11 ng/ml (range: 0.1-100 ng/ml) (median +/- SE), 16 showed positive in the whole body PET/CT. All of the patients with positive whole body scans due to pelvic involvement had positive early scan results. Totally, 22 lesions were detected in both early and delay scans in the pelvic which 16 were related to prostate involvement, 4 were related to lymph node involvement, and 2 were related to bone involvement. Moreover, in addition to the mentioned 22 lesions, early PET imaging successfully detected local recurrence in a patient who was negative on WB PET/ CT; this lesion was masked in the delay scan due to bladder activity. The median SUVmax values of the early and delay scans were 3.69 +/- 1.07 (median +/- SE) (range: 1.2-14.5) and 5.85 +/- 1.69 (range: 3.1-23.4), respectively. (p = 0.005). Conclusion: Early static 68Ga-PSMA-11 PET/CT imaging might discriminate metastases from urinary bladder activity. Therefore, early static imaging in combination with whole body 60-min p.i. imaging can improve the detection of local involvement pelvic disease.
引用
收藏
页码:355 / 361
页数:7
相关论文
共 50 条
  • [21] 68Ga-PSMA-11 PET/CT in Cherry Hemangiomas
    Betech-Antar, Vicky
    Urtasun-Iriarte, Cesar
    Rosales, Juan J.
    Barrio-Piqueras, Miguel
    Rodriguez-Fraile, Macarena
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (11) : e591 - e592
  • [22] Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning
    Capobianco, Nicolo
    Sibille, Ludovic
    Chantadisai, Maythinee
    Gafita, Andrei
    Langbein, Thomas
    Platsch, Guenther
    Solari, Esteban Lucas
    Shah, Vijay
    Spottiswoode, Bruce
    Eiber, Matthias
    Weber, Wolfgang A.
    Navab, Nassir
    Nekolla, Stephan G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (02) : 517 - 526
  • [23] Lung uptake detected by 68Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series
    Farolfi, Andrea
    Telo, Silvi
    Castellucci, Paolo
    Morais de Campos, Ana Luiza
    Rosado-de-Castro, Paulo Henrique
    de Almeida, Sergio Altino
    Artigas, Carlos
    Scarlattei, Maura
    Leal, Aline
    Deandreis, Desiree
    Fanti, Stefano
    Fendler, Wolfgang Peter
    Mosconi, Cristina
    Pianori, Davide
    Ruffini, Livia
    Ceci, Francesco
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 11 (04): : 300 - 306
  • [24] Pattern of Prostate Cancer Recurrence Assessed by 68Ga-PSMA-11 PET/CT in Men Treated with Primary Local Therapy
    Lawal, Ismaheel O.
    Lengana, Thabo
    Popoola, Gbenga O.
    Orunmuyi, Akintunde T.
    Kgatle, Mankgopo M.
    Mokoala, Kgomotso M. G.
    Sathekge, Mike M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [25] Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI
    Jannusch, Kai
    Bruckmann, Nils Martin
    Morawitz, Janna
    Boschheidgen, Matthias
    Quick, Harald H.
    Herrmann, Ken
    Fendler, Wolfgang P.
    Umutlu, Lale
    Stuschke, Martin
    Hadaschik, Boris
    Antoch, Gerald
    Schimmoeller, Lars
    Kirchner, Julian
    EUROPEAN RADIOLOGY, 2024, 34 (07) : 4789 - 4800
  • [26] Development and validation of 68Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer
    Zang, Shiming
    Ai, Shuyue
    Yang, Rui
    Zhang, Pengjun
    Wu, Wenyu
    Zhao, Zhenyu
    Ni, Yudan
    Zhang, Qing
    Sun, Hongbin
    Guo, Hongqian
    Jia, Ruipeng
    Wang, Feng
    EJNMMI RESEARCH, 2022, 12 (01)
  • [27] Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
    Calais, Jeremie
    Czernin, Johannes
    Fendler, Wolfgang P.
    Elashoff, David
    Nickols, Nicholas Nicholas G.
    BMC CANCER, 2019, 19 (1)
  • [28] Comparative diagnostic performance of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in detecting biochemical recurrent bone metastasis in prostate cancer: a systematic review and meta-analysis
    Wen, Xin
    Jiang, Cheng-Yi
    Jiang, Xu
    Chen, Yan
    Li, Meng
    ACTA RADIOLOGICA, 2025, : 312 - 327
  • [29] 68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?
    Christian Uprimny
    Wiener Medizinische Wochenschrift, 2019, 169 : 3 - 11
  • [30] 68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol
    Fabian Haupt
    Lotte Dijkstra
    Ian Alberts
    Christos Sachpekidis
    Viktor Fech
    Silvan Boxler
    Tobias Gross
    Tim Holland-Letz
    Helle D. Zacho
    Uwe Haberkorn
    Kambiz Rahbar
    Axel Rominger
    Ali Afshar-Oromieh
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 624 - 631